Boehringer Ingelheim announced that the CHMP of the European Medicines Agency has adopted a positive opinion for the Marketing Authorisation Application of Cyltezo (adalimumab biosimilar), to treat multiple chronic inflammatory diseases in adults and children.
Archive for Category: "News/Headlines"

Samsung Bioepis received first positive CHMP opinion on a trastuzumab biosimilar

Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
